Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
26 02 2021
Historique:
accepted: 08 01 2021
revised: 17 12 2020
received: 17 09 2020
pubmed: 30 1 2021
medline: 10 3 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

PARP-1 is a key early responder to DNA damage in eukaryotic cells. An allosteric mechanism links initial sensing of DNA single-strand breaks by PARP-1's F1 and F2 domains via a process of further domain assembly to activation of the catalytic domain (CAT); synthesis and attachment of poly(ADP-ribose) (PAR) chains to protein sidechains then signals for assembly of DNA repair components. A key component in transmission of the allosteric signal is the HD subdomain of CAT, which alone bridges between the assembled DNA-binding domains and the active site in the ART subdomain of CAT. Here we present a study of isolated CAT domain from human PARP-1, using NMR-based dynamics experiments to analyse WT apo-protein as well as a set of inhibitor complexes (with veliparib, olaparib, talazoparib and EB-47) and point mutants (L713F, L765A and L765F), together with new crystal structures of the free CAT domain and inhibitor complexes. Variations in both dynamics and structures amongst these species point to a model for full-length PARP-1 activation where first DNA binding and then substrate interaction successively destabilise the folded structure of the HD subdomain to the point where its steric blockade of the active site is released and PAR synthesis can proceed.

Identifiants

pubmed: 33511412
pii: 6123376
doi: 10.1093/nar/gkab020
pmc: PMC7913765
doi:

Substances chimiques

Amides 0
Poly(ADP-ribose) Polymerase Inhibitors 0
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2266-2288

Subventions

Organisme : Medical Research Council
ID : MC_U105178934
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001029
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001029
Pays : United Kingdom
Organisme : CIHR
ID : BMA342854
Pays : Canada
Organisme : Medical Research Council
ID : FC001029
Pays : United Kingdom
Organisme : Medical Research Council
ID : U105178934
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U117533887
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Acta Crystallogr F Struct Biol Commun. 2014 Sep;70(Pt 9):1143-9
pubmed: 25195882
Mol Cell Biochem. 1994 Sep;138(1-2):15-24
pubmed: 7898458
Anal Chem. 2009 Jul 15;81(14):5577-84
pubmed: 19601649
J Mol Biol. 2010 Feb 5;395(5):983-94
pubmed: 19962992
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
J Biomol NMR. 2012 Jul;53(3):209-21
pubmed: 22689066
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Biophys J. 2017 May 23;112(10):2075-2088
pubmed: 28538145
J Mol Biol. 1998 Apr 24;278(1):57-65
pubmed: 9571033
Methods Mol Biol. 2017;1608:431-444
pubmed: 28695525
Biochem J. 1999 Sep 1;342 ( Pt 2):249-68
pubmed: 10455009
Methods Mol Biol. 2010;627:91-100
pubmed: 20217615
Proteins. 2005 Jun 1;59(4):687-96
pubmed: 15815974
Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1367-72
pubmed: 11567147
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Mol Cell. 2015 Dec 3;60(5):755-768
pubmed: 26626480
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Mol Oncol. 2011 Aug;5(4):387-93
pubmed: 21821475
Nat Struct Mol Biol. 2012 Jun 10;19(7):685-692
pubmed: 22683995
J Mol Biol. 2011 Mar 18;407(1):149-70
pubmed: 21262234
Prog Nucl Magn Reson Spectrosc. 2013 Aug;73:1-16
pubmed: 23962882
Science. 2020 Apr 3;368(6486):
pubmed: 32241924
Nat Commun. 2018 Feb 27;9(1):844
pubmed: 29487285
Genes Dev. 2011 Mar 1;25(5):409-33
pubmed: 21363960
Nat Rev Genet. 2008 Aug;9(8):619-31
pubmed: 18626472
Prog Nucl Magn Reson Spectrosc. 2011 Oct;59(3):271-92
pubmed: 21920222
Annu Rev Biophys Bioeng. 1979;8:99-127
pubmed: 38741
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
Methods Mol Biol. 2011;780:209-26
pubmed: 21870263
J Med Chem. 2017 Feb 23;60(4):1262-1271
pubmed: 28001384
Proteins. 1993 Sep;17(1):75-86
pubmed: 8234246
J Med Chem. 2019 Jun 13;62(11):5330-5357
pubmed: 31042381
Biochemistry. 1994 May 17;33(19):5984-6003
pubmed: 7514039
Mol Cell. 2015 Dec 3;60(5):742-754
pubmed: 26626479
Nature. 2020 Mar;579(7800):598-602
pubmed: 32028527
Mol Cancer Res. 2015 Nov;13(11):1465-77
pubmed: 26217019
Biochemistry. 1989 Nov 14;28(23):8972-9
pubmed: 2690953
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Bioorg Med Chem Lett. 2004 Jan 5;14(1):81-5
pubmed: 14684303
EMBO J. 1993 May;12(5):2109-17
pubmed: 8491199
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
J Biomol Screen. 2014 Sep;19(8):1212-9
pubmed: 24916412
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Science. 2012 May 11;336(6082):728-32
pubmed: 22582261
EMBO Mol Med. 2009 Sep;1(6-7):315-22
pubmed: 20049735
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7481-5
pubmed: 8755499
J Biomol NMR. 1998 Feb;11(2):221-6
pubmed: 9679296
J Magn Reson. 2007 Jan;184(1):108-13
pubmed: 17049891
J Biomol NMR. 2010 Jan;46(1):11-22
pubmed: 19915800
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Mol Cell. 2010 Jul 9;39(1):8-24
pubmed: 20603072
Biochemistry. 1998 Mar 17;37(11):3893-900
pubmed: 9521710
J Pharmacol Exp Ther. 2015 Jun;353(3):446-57
pubmed: 25758918

Auteurs

Tom E H Ogden (TEH)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.

Ji-Chun Yang (JC)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.

Marianne Schimpl (M)

Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

Laura E Easton (LE)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.

Elizabeth Underwood (E)

Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

Philip B Rawlins (PB)

Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

Michael M McCauley (MM)

Department of Biochemistry & Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Marie-France Langelier (MF)

Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.

John M Pascal (JM)

Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.

Kevin J Embrey (KJ)

Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

David Neuhaus (D)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis
Databases, Protein Protein Domains Protein Folding Proteins Deep Learning

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female

Classifications MeSH